Pharmaceutical Industry and FDA Preparing for ICH M7 Implementation
This article was originally published in The Gold Sheet
Executive Summary
The pharmaceutical industry is concerned about the cost involved in setting up complex computational systems required for evaluating potential genotoxic impurities in drug substances and drug products under ICH M7. The guidance goes into effect in January 2016 for drugs in clinical development and in July 2017 for new and generic drug applications as well as drugs with post-approval changes.
You may also be interested in...
ICH M7 Guide Sets Validation Principles For Genotoxicity Impurity Testing For New Drugs
The US FDA has issued a draft question and answer document to the ICH M7 guideline that sheds some light on the validation that needs to be performed before manufactures can rely on the results of computational tests in assessing genotoxic impurities of new drugs.
The Reaction To Valsartan Impurities: More Scrutiny, More Testing And Tighter Limits
In the months since US and EU authorities restricted Zhejiang Huahai’s market access over the discovery of nitrosamine impurities in its valsartan API, the broader regulatory consequences for drug manufacturers are coming into focus.
FDA Officials Offer Tips On How To Improve CMC Packages To Win ANDA Approvals
With FDA increasingly refusing to receive ANDAs, typically because of CMC deficiencies, agency officials recently shared some advice on how sponsors can improve their submissions.